HIGHLIGHTS
- who: Mehrdad Rabiee Rad from the (UNIVERSITY) have published the research: Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials, in the Journal: (JOURNAL) of May/30,/2022
- what: Evidence from four RCTs indicated that mavacamten could improve the clinical response and NYHA function class in patient with HCM.
- how: Indicated that provision of mavacamten improves NYHA function class and clinical response among patients with HCM.
- future: More studies with a larger number of participants are needed to draw definite . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.